Polycystic Liver Disease: The Benefits of Targeting cAMP

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 7, 2016, Pages 1031-1034

  Larusso, Nicholas F ^a   Masyuk, Tatyana V ^a   Hogan, Marie C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYCLIC AMP; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELLS BY BODY ANATOMY; CHOLANGIOCYTE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; HEPATOMEGALY; HUMAN; INTRACELLULAR SIGNALING; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECRETION (PROCESS); CYST; KIDNEY POLYCYSTIC DISEASE; LIVER DISEASE;

CYSTS; HUMANS; LIVER DISEASES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 84973866200     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.03.008     Document Type: Editorial

References (20)

1. Gevers T.J., Drenth J.P. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol 2013, 10:101-108.
2. Masyuk T.V., Masyuk A.I., La Russo N.F. Therapeutic targets in polycystic liver disease. Curr Drug Targets 2015, [Epub ahead of print].
3. Everson G.T., Emmett M., Brown W.R., et al. Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin. Hepatology 1990, 11:557-565.
4. Banales J.M., Masyuk T.V., Gradilone S.A., et al. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009, 49:160-174.
5. Banales J.M., Masyuk T.V., Bogert P.S., et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008, 173:1637-1646.
6. Masyuk T.V., Radtke B.N., Stroope A.J., et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013, 58:409-421.
7. Masyuk T.V., Masyuk A.I., Torres V.E., et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007, 132:1104-1116.
8. van Keimpema L., de Man R.A., Drenth J.P. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008, 57:1338-1339.
9. Gevers T.J., Drenth J.P. Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol 2011, 27:294-300.
10. Peces R., Cuesta-Lopez E., Peces C., et al. Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease. Int Urol Nephrol 2011, 43:565-569.
11. van Keimpema L., Drenth J.P. Effect of octreotide on polycystic liver volume. Liver Int 2010, 30:633-634.
12. Pisani A., Sabbatini M., Imbriaco M., et al. Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease. Clin Gastroenterol Hepatol 2016, 14:1022-1030.
13. van Keimpema L., Nevens F., Vanslembrouck R., et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009, 137:1661-1668. e1661-1662.
14. Chrispijn M., Nevens F., Gevers T.J., et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012, 35:266-274.
15. Caroli A., Antiga L., Cafaro M., et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010, 5:783-789.
16. Hogan M.C., Masyuk T.V., Page L.J., et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010, 21:1052-1061.
17. Hogan M.C., Masyuk T.V., Page L., et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012, 27:3532-3539.
18. Hogan M.C., Masyuk T., Bergstralh E., et al. Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease. Mayo Clin Proc 2015, 90:1030-1037.
19. Temmerman F., Ho T.A., Vanslembrouck R., et al. Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease. Clin Gastroenterol Hepatol 2015, 13:2353-2359. e2351.
20. Chrispijn M., Gevers T.J., Hol J.C., et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol 2013, 59:153-159.